Collaboration and License Agreements (Tables)

12 Months Ended

Dec. 31, 2025

Revenue Recognition [Abstract]

Schedule of Asset Acquisition

The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the Sanofi Agreement as of the acquisition date (in thousands):

Upfront	$	100,000
Equipment	1,150
Deposits	2,580
Transaction costs	4,612
Total purchase consideration	$	108,342

The total purchase price was allocated to the acquired assets based on their relative fair values as of the Acquisition Date as follows (in thousands):

IPR&D	$	102,836
Property and equipment	1,119
Prepaid expenses and other current assets (1)	3,975
Assembled workforce	412
Total purchase consideration	$	108,342

__________________________________________________________

(1) Includes acquired cash deposits primarily related to contract manufacturing agreements.

Schedule of Collaboration Revenue

During the years ended December 31, 2025, 2024, and 2023, the Company recorded profit-sharing amounts, profit-sharing amounts constrained, and profit-sharing amounts previously constrained, released as components of license and collaboration revenue in the consolidated statements of operations, as follows (in thousands):

	Years Ended December 31,
	2025		2024		2023
License and collaboration revenue under GSK 2020 Agreement
Profit-sharing amount	$	(1,138)	$	9,078	$	1,536
Profit-sharing amount constrained	—		(699)		—
Profit-sharing amount previously constrained, released	—		—		35,730
Total license and collaboration revenue under GSK 2020 Agreement	$	(1,138)	$	8,379	$	37,266